🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
4.990
-0.100 (-1.96%)
At close: Nov 20, 2026, 4:00 PM EST
5.09
+0.10 (2.00%)
After-hours: Nov 20, 2026, 7:30 PM EST

Company Description

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.

It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.

The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.

Anteris Technologies Global Corp. is based in Toowong, Australia.

Anteris Technologies Global Corp.
Anteris Technologies Global logo
CountryAustralia
Founded1999
IPO DateDec 13, 2024
IndustryMedical Devices
SectorHealthcare
Employees174
CEOWayne Paterson

Contact Details

Address:
Toowong Tower, Level 3, Suite 302
Toowong, QLD 4066
Australia
Phone61 7 3152 3200
Websiteanteristech.com

Stock Details

Ticker SymbolAVR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$6.00
CIK Code2011514
CUSIP Number03675P102
ISIN NumberUS03675P1021
SIC Code3842

Key Executives

NamePosition
Wayne Geoffrey PatersonVice Chairman and Chief Executive Officer
David St. DenisPresident and Director
Matthew McDonnellHead of Australia
Brent A. MoenChief Financial Officer
Eric Ian Schwartz J.D.Chief Legal Officer
Dr. Chris Meduri M.D., M.P.H.Chief Medical Officer and Member of Medical Advisory Board

Latest SEC Filings

DateTypeTitle
Nov 17, 2026424B3Prospectus
Nov 17, 2026424B3Prospectus
Nov 12, 20268-KCurrent Report
Nov 10, 202610-QQuarterly Report
Nov 9, 2026ARSFiling
Nov 9, 2026DEF 14AOther definitive proxy statements
Nov 9, 202610-Q/A[Amend] Quarterly report
Nov 9, 202610-Q/A[Amend] Quarterly report
Nov 9, 202610-K/A[Amend] Annual report
Nov 5, 2026SCHEDULE 13G/AFiling